---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-124259"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:24:12.501643+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Akebia amends bylaws to update proxy rules, stockholder meeting procedures

## Summary
- Eliminates requirement to provide stockholder list during actual meeting.
- Addresses adjournment of meetings due to technical failure in remote communication.
- Enhances disclosure requirements for stockholder nominations under universal proxy rules.
- Imposes compliance deadlines and consequences for non-compliance with Rule 14a-19.

## SEC filing metadata
- accession: 0001193125-23-124259
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312523124259/0001193125-23-124259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312523124259/d455889d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-124259
- JSON: https://secwatch.observer/filing/0001193125-23-124259.json
- Plain text: https://secwatch.observer/filing/0001193125-23-124259.txt

## Key facts
- Governance Changes
  Akebia Therapeutics, Inc.: Board approved amendment and restatement of bylaws, eliminating stockholder list availability requirement at meeting, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics under universal proxy rules (effective 2023-04-27).
  - Change: bylaw amendment
  - Effective: 2023-04-27
  source text: On April 27, 2023, the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Second Amended and Restated Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523124259/0001193125-23-124259-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.